Lasofoxifene
Lasofoxifene
Lasofoxifene is being investigated as a targeted endocrine therapy with a differentiated safety profile that could prove useful in the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic hormone receptor-positive (ER+) breast cancer.
Lasofoxifene has been part of several clinical development programs and is being investigated as part of the ELAINE Study not only for its impacts on breast cancer but also its impacts on quality of life.
Hypothetical Mechanism of Action (MOA) of Lasofoxifene
Clinical scientists at the University of Chicago are using crystallography to better understand the MOA of lasofoxifene.